Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands

Table 3

Results presented for each cost category across all three scenarios. Total costs per patient are calculated, and all results are in Euros.

Clinical practice	Chemotherapy acquisition costs (€)	Chemotherapy administration costs (€)	Short-term AE costs (€)	Long-term AE costs (€)	Productivity losses (€)	GPT test costs (€)	Recurrence costs (€)	Total costs for entire model population (€)	Total costs per patient (€)
Oncotype DX test	€3,343,380	€4,514,251	€1,492,789	€563,146	€3,321,681	€9,116,840	€6,863,702	€29,215,789	€14,379
No genomic test	€12,382,889	€16,719,449	€5,528,848	€2,085,726	€12,302,523	€0	€6,863,702	€55,883,137	€27,504
MammaPrint	€6,686,760	€9,028,502	€2,985,578	€1,126,292	€6,643,362	€7,667,051	€8,828,722	€42,966,268	€21,147
Difference between Oncotype DX test vs. no genomic test	-€9,039,509	-€12,205,198	-€4,036,059	-€1,522,580	-€8,980,842	€9,116,840	€0	-€26,667,347	-€13,125
Difference between Oncotype DX test vs. MammaPrint	-€3,343,380	-€4,514,251	-€1,492,789	-€563,146	-€3,321,681	€1,449,788	-€1,965,020	-€13,750,478	-€6,768

Abbreviations: AE = adverse event; GPT = genomic profile test.